Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents

Guoyan G. Xu,Saheem A. Zaidi,Feng Zhang,Shilpa Singh,Thomas J. Raborg,Yunyun Yuan,Yan Zhang

DOI: https://doi.org/10.1016/j.bmcl.2015.06.029

IF: 2.94

2015-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:Prostate cancer is one of the leading causes of death among males in the world. Prostate cancer cells have been shown to express upregulated chemokine receptor CCR5, a G protein-coupled receptor (GPCR) that relates to the inflammation process. Anibamine, a natural product containing a pyridine ring and two aliphatic side chains, was shown to carry a binding affinity of 1μM at CCR5 as an antagonist with potential anti-cancer activity. However, it is not drug-like according to the Lipinski’s rule of five mainly due to its two long aliphatic side chains. In our effort to improve its drug-like property, a series of anibamine derivatives were designed and synthesized by placement of aromatic side chains through an amide linkage to the pyridine ring. The newly synthesized compounds were tested for their CCR5 affinity and antagonism, and potential anti-proliferation activity against prostate cancer cell lines. Basal cytotoxicity was finally studied for compounds showing potent anti-proliferation activity. It was found that compounds with hydrophobic substitutions on the aromatic systems seemed to carry more promising CCR5 binding and prostate cancer cell proliferation inhibition activities.